Fig. 6: Astrocytes form limitans borders that isolate hydrogels and non-neural FBR components from viable neural tissue.

a, b Progression of astrocyte limitans border formation from 1 week a to 6 weeks b for DCHMO, DCHK, and L-NIO-induced stroke. c, d OPC identified by NG2-targeted reporter (tdT) c and Olig2 d intermingle with GFAP-positive astrocytes and do not migrate into CD13-positive regions. e Comparison of extent of blood–brain barrier (BBB) disruption and repair as measured by IgG staining around DCHMO and DCHK deposits at 1 and 6 weeks after injection. f Quantification of the percentage increase in IgG levels in the hydrogel injected caudate putamen (CP) normalized to the non-injected contralateral side. **P = 0.0012 and ***P = 0.0001 for DCHK versus DCHMO at 1 week and 6 week, respectively, and not significant (NS) for DCHK samples between the two timepoints, two-way ANOVA with Bonferroni. Graph shows mean ± s.e.m with individual data points superimposed showing n = 5 and 6 mice for DCHMO and DCHK, respectively.